Lydia Visser
PhD
My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.
Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups (Retraction of vol 118, pg 5211, 2011)
Published in: Blood
Access to document
10.1182/blood-2012-01-405878
X. Huang, K. Kushekhar, Roeland J. M. Nolte, W. Kooistra, Lydia Visser, Ilby Bouwman, N. Kouprie, R. Veenstra, G. van Imhoff, G. Imhoff, B. Olver, R. S. Houlston, S. Poppema, A. Diepstra, B. Hepkema, A. van den Berg
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin’s lymphoma
Published in: Haematologica
Access to document
10.3324/haematol.2011.056101
document
BACKGROUND: The c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis and prognosis of many human malignancies. We studied the function and prognostic significance of c-Met and hepatocyte growth factor protein expression in patients with classical Hodgkin’s lymphoma. DESIGN AND METHODS: Expression of c-Met and its ligand, hepatocyte growth factor, were determined by immunohistochemistry. Prognostic values were defined in cohorts of German and Dutch patients with classical Hodgkin’s lymphoma. Functional studies were performed on...
Chuanhui Xu, Wouter Plattel, Anke van den Berg, Nele Ruether, Xin Huang, Miao Wang, Debora de Jong, Hans Vos, Gustaaf van Imhoff, Andreas Viardot, Peter Moeller, Sibrand Poppema, Arjan Diepstra, Lydia Visser
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma
Published in: Haematologica
Access to document
10.3324/haematol.2011.053199
document
BACKGROUND: Plasma thymus and activation-regulated chemokine is a potential biomarker for classical Hodgkin’s lymphoma. To define its value as a marker to monitor treatment response, we correlated serial plasma thymus and activation-regulated chemokine levels with clinical response in newly diagnosed and relapsed classical Hodgkin’s lymphoma patients. DESIGN AND METHODS: Plasma was collected from 60 (39 early stage and 21 advanced stage) newly diagnosed classical Hodgkin’s lymphoma patients before, during, and after treatment, and from 12 relapsed patients before and after treatment. Plasma thymus and activation-regulated chemokine levels were...
Wouter J. Plattel, Anke van den Berg, Lydia Visser, Anne-Marijn van der Graaf, Jan Pruim, Hans Vos, Bouke Hepkema, Arjan Diepstra, Gustaaf W. van Imhoff
HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0031865
document
HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n = 161) from the northern part of China. Quantitative-PCR and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and...
Xin Huang, Bouke Hepkema, Ilja Nolte, Kushi Kushekhar, Theo Jongsma, Rianne Veenstra, Sibrand Poppema, Zifen Gao, Lydia Visser, Arjan Diepstra, Anke van den Berg
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups
Published in: Journal of the National Cancer Institute
Access to document
10.1093/jnci/djr516
BACKGROUND: Accumulating evidence suggests that risk factors for classical Hodgkin lymphoma (cHL) differ by tumor Epstein-Barr virus (EBV) status. This potential etiological heterogeneity is not recognized in current disease classification. METHODS: We conducted a genome-wide association study of 1200 cHL patients and 6417 control subjects, with validation in an independent replication series, to identify common genetic variants associated with total cHL and subtypes defined by tumor EBV status. Multiple logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) assuming a log-additive genetic model...
Kevin Y. Urayama, Ruth F. Jarrett, Henrik Hjalgrim, Arjan Diepstra, Yoichiro Kamatani, Amelie Chabrier, Valerie Gaborieau, Anne Boland, Alexandra Nieters, Nikolaus Becker, Lenka Foretova, Yolanda Benavente, Marc Maynadie, Anthony Staines, Lesley Shield, Annette Lake, Dorothy Montgomery, Malcolm Taylor, Karin Ekstrom Smedby, Rose-Marie AminiHans-Olov Adami, Bengt Glimelius, Bjarke Feenstra, Ilja M. Nolte, Lydia Visser, Gustaaf W. van Imhoff, Tracy Lightfoot, Pierluigi Cocco, Lambertus Kiemeney, Sita H. Vermeulen, Ivana Holcatova, Lars Vatten, Gary J. Macfarlane, Peter Thomson, David I. Conway, Simone Benhamou, Antonio Agudo, Claire M. Healy, Kim Overvad, Anne Tjonneland, Beatrice Melin, Federico Canzian, Kay-Tee Khaw, Ruth C. Travis, Petra H. M. Peeters, Carlos A. Gonzalez, Jose Ramon Quiros, Maria-Jose Sanchez, Jose Maria Huerta, Eva Ardanaz, Miren Dorronsoro, Francoise Clavel-Chapelon, H. Bas Bueno-de-Mesquita, Elio Riboli, Eve Roman, Paolo Boffetta, Silvia de Sanjose, Diana Zelenika, Mads Melbye, Anke van den Berg, Mark Lathrop, Paul Brennan, James D. McKay